Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $686 | $709 | $523 | $415 |
| - Cash | $77 | $89 | $1 | $1 |
| + Debt | $50 | $10 | $0 | $21 |
| Enterprise Value | $659 | $630 | $523 | $435 |
| Revenue | $309 | $271 | $239 | $200 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Gross Profit | $175 | $157 | $1 | $1 |
| % Margin | 56.7% | 58.1% | 0.4% | 0.5% |
| EBITDA | $56 | $50 | $42 | $36 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |
| Net Income | $31 | $31 | $26 | $21 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS Diluted | 135.44 | 135.21 | 115.29 | 92.34 |
| % Growth | 0.2% | 17.3% | 24.9% | – |
| Operating Cash Flow | $37 | $34 | $0 | $0 |
| Capital Expenditures | -$11 | -$9 | -$0 | -$0 |
| Free Cash Flow | $26 | $25 | $0 | $0 |